| # | Title | Journal | Year | Citations |
|---|
| 1 | Combined therapy for cancer of the anal canal | Diseases of the Colon and Rectum | 1974 | 928 |
| 2 | Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives | Current Cancer Drug Targets | 2011 | 671 |
| 3 | Broad targeting of resistance to apoptosis in cancer | Seminars in Cancer Biology | 2015 | 535 |
| 4 | Connecting copper and cancer: from transition metal signalling to metalloplasia | Nature Reviews Cancer | 2022 | 519 |
| 5 | Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4 | Nature | 2017 | 516 |
| 6 | Malignant melanoma and central nervous system metastases.Incidence, diagnosis, treatment and survival | Cancer | 1978 | 390 |
| 7 | Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer | Cancer Control | 2016 | 303 |
| 8 | Designing a broad-spectrum integrative approach for cancer prevention and treatment | Seminars in Cancer Biology | 2015 | 220 |
| 9 | Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) | Journal of Medicinal Chemistry | 2012 | 217 |
| 10 | Overview of Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy | Current Protocols in Pharmacology | 2013 | 210 |
| 11 | Targeting adaptive glioblastoma: an overview of proliferation and invasion | Neuro-Oncology | 2014 | 206 |
| 12 | Cutaneous adverse effects of targeted therapies | Journal of the American Academy of Dermatology | 2015 | 191 |
| 13 | The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women | Cancer Epidemiology Biomarkers and Prevention | 2015 | 181 |
| 14 | Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone | JAMA Oncology | 2015 | 177 |
| 15 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers | Molecular Cancer Research | 2018 | 169 |
| 16 | Galectin-3 in angiogenesis and metastasis | Glycobiology | 2014 | 167 |
| 17 | Tissue‐specific regulation of cytochrome c by post‐translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis | FASEB Journal | 2019 | 159 |
| 18 | Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment | PLoS ONE | 2012 | 152 |
| 19 | Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study | The Lancet Gastroenterology and Hepatology | 2020 | 152 |
| 20 | Cutaneous adverse effects of targeted therapies | Journal of the American Academy of Dermatology | 2015 | 150 |
| 21 | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers | Oncotarget | 2017 | 147 |
| 22 | Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men | Cancer Epidemiology Biomarkers and Prevention | 2013 | 142 |
| 23 | Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma | Oncologist | 2018 | 131 |
| 24 | Genetic alterations of histone lysine methyltransferases and their significance in breast cancer | Oncotarget | 2015 | 128 |
| 25 | Hypoxia Induced Aggressiveness of Prostate Cancer Cells Is Linked with Deregulated Expression of VEGF, IL-6 and miRNAs That Are Attenuated by CDF | PLoS ONE | 2012 | 116 |
| 26 | Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium | Cancer Causes and Control | 2013 | 114 |
| 27 | Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer | Current Drug Targets | 2010 | 112 |
| 28 | Phase II evaluation of bleomycin.A Southwest Oncology Group study | Cancer | 1976 | 108 |
| 29 | Prevalence of and Factors Associated With Patient Nondisclosure of Medically Relevant Information to Clinicians | JAMA Network Open | 2018 | 108 |
| 30 | Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets | Journal of Gastrointestinal Oncology | 2019 | 106 |
| 31 | Immunotherapy in Lung Cancer: Current Landscape and Future Directions | Frontiers in Immunology | 2022 | 105 |
| 32 | Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer | Cancer | 1979 | 104 |
| 33 | Galectin-3 and cancer stemness | Glycobiology | 2018 | 100 |
| 34 | Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells | Bioorganic and Medicinal Chemistry | 2012 | 97 |
| 35 | Primary liver cancer.A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases | Cancer | 1974 | 95 |
| 36 | The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis | Cancer and Metastasis Reviews | 2011 | 95 |
| 37 | Recent advances on tea polyphenols | Frontiers in Bioscience - Elite | 2012 | 94 |
| 38 | The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status | Current Colorectal Cancer Reports | 2013 | 94 |
| 39 | Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer | Clinical Lung Cancer | 2013 | 93 |
| 40 | Deubiquitinases (DUBs) and DUB inhibitors: a patent review | Expert Opinion on Therapeutic Patents | 2015 | 93 |
| 41 | Current Perspective on the Global and United States Cancer Burden Attributable to Lifestyle and Environmental Risk Factors | Annual Review of Public Health | 2013 | 92 |
| 42 | Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma | Blood | 2020 | 90 |
| 43 | A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316) | Oncologist | 2012 | 89 |
| 44 | Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis | Molecular Cancer | 2016 | 89 |
| 45 | A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors | Clinical Pharmacology and Therapeutics | 2010 | 87 |
| 46 | Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met | Breast Cancer Research | 2012 | 87 |
| 47 | A disparity of words: racial differences in oncologist–patient communication about clinical trials | Health Expectations | 2015 | 86 |
| 48 | PET Imaging of Proliferation with Pyrimidines | Journal of Nuclear Medicine | 2013 | 85 |
| 49 | Interleukin-33-induced expression of PIBF1 by decidual B cells protects against preterm labor | Nature Medicine | 2017 | 85 |
| 50 | Transient gene silencing of galectin‐3 suppresses pancreatic cancer cell migration and invasion through degradation of β‐catenin | International Journal of Cancer | 2011 | 81 |
